Recently, it has reported that androgen receptor may be the therapeutic target of androgen-driven triple-negative breast cancer patients, and anti-androgens, widely used to treat metastatic CRPC, can be used for TNBC treatment34. This evidence concerns the gene AR and triple-negative breast carcinoma.